ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 132,77
-0,14%
Dow Jones
43 433,12
-0,43%
DAX
22 597,90
-0,88%
Brent Oil
72,705
0,53%
Bitcoin
86 374,51
2,74%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Stoke Therapeutics Inc (STOK)

  7. Stoke Therapeutics Inc (STOK) Actualités

STOK

Stoke Therapeutics (STOK)

Stoke Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:STOK
DateHeureSourceTitreSymboleSociété
26/02/202522h30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in MarchNASDAQ:STOKStoke Therapeutics Inc
18/02/202522h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
18/02/202514h00Business WireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
08/01/202522h30Business WireStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
07/01/202513h00Business WireStoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
06/01/202522h30Business WireStoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
27/12/202423h23Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
27/12/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
24/12/202400h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/12/202418h00Business WireStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/12/202413h00Business WireStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
02/12/202414h00Business WireStoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual MeetingNASDAQ:STOKStoke Therapeutics Inc
14/11/202415h00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STOKStoke Therapeutics Inc
05/11/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STOKStoke Therapeutics Inc
05/11/202413h00Business WireStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
09/10/202422h16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:STOKStoke Therapeutics Inc
23/09/202422h22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
10/09/202413h00Business WireStoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/09/202414h00Business WireStoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business OfficerNASDAQ:STOKStoke Therapeutics Inc
03/09/202414h00Business WireStoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
03/09/202414h00Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in SeptemberNASDAQ:STOKStoke Therapeutics Inc
16/08/202422h30Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:STOKStoke Therapeutics Inc
07/08/202413h00Business WireStoke Therapeutics Reports Second Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
13/06/202422h06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:STOKStoke Therapeutics Inc
03/06/202422h30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in JuneNASDAQ:STOKStoke Therapeutics Inc
17/05/202422h12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/05/202413h00Business WireStoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
29/04/202414h00Business WireStoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerNASDAQ:STOKStoke Therapeutics Inc
17/04/202414h00Business WireStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerNASDAQ:STOKStoke Therapeutics Inc
04/04/202422h30Business WireStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:STOK

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
EU
DG
Vinci
EU
BEL20
Bel 20
EU
EN
Bouygues
EU
LR
Legrand
EU
VK
Vallourec
COIN
AVAXUSD
Avalanche
NYSE
KO
Coca Cola
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces